Alternatives to blood product transfusion in the critically ill: Erythropoietin

Critical Care Medicine

Volumn 34, Issue 5 SUPPL., 2006, Pages

  Stubbs, James R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anemia; Critically ill; Intensive care; Recombinant erythropoietin; Red cell transfusions

Indexed keywords

CYANOCOBALAMIN; ERYTHROPOIETIN; FOLIC ACID; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DRUG COST; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; IRON METABOLISM; MEDIATOR RELEASE; OUTCOMES RESEARCH; PATIENT CARE; PHLEBOTOMY; PRIORITY JOURNAL; RETICULOCYTE COUNT; TREATMENT OUTCOME;

ANEMIA; BLOOD COMPONENT TRANSFUSION; CRITICAL ILLNESS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INTENSIVE CARE UNITS; RANDOMIZED CONTROLLED TRIALS;

EID: 33646361575     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000214290.11479.5C     Document Type: Article

References (35)

1. von Ahsen N, Müller C, Serke S, et al: Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27:2630-2639
2. Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350
3. Rodriguez RM, Corwin HL, Gettinger A, et al: Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001; 16:36-41
4. Corwin HL, Gettinger A, Pearl RG, et al: The CRIT study: Anemia and blood transfusion in the critically ill: Current clinical practice in the United States. Crit Care Med 2004; 32:39-52
5. Littenberg B, Corwin H, Gettinger A, et al: A practice guideline and decision aid for blood transfusion. Immunohematology 1995; 11:88-94
6. Corwin HL, Parsonnet KC, Gettinger A: RBC transfusion in the ICU: Is there a reason? Chest 1995; 108:767-771
7. Groeger JS, Guntupalli KK, Strosberg M, et: al: Descriptive analysis of critical care units in the United States: Patient characteristics and intensive care unit utilization. Crit Care Med 1993; 21:279-291
8. Vincent JL, Baron JF, Reinhart K, et al: Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507
9. Smoller BR, Kruskall MS: Phlebotomy for diagnostic laboratory tests in adults: Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314:1233-1235
10. Rogiers P, Zhang H, Leeman M, et al: Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23:159-162
11. Hobisch-Hagen P, Wiedermann F, Mayr A, et al: Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med 2001; 29:743-747
12. Gabriel A, Kozek S, Chiari A, et al: High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998; 44:361-367
13. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28:2773-2778
14. Means RT Jr., Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-1647
15. Krantz SB: Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994; 307:353-359
16. Frede S, Fandrey J, Pagel H, et al: Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol 1997; 272:R1067-R1071
17. Jelkmann W: Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18:555-559
18. Blick M, Sherwin SA, Rosenblum M, et al: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47:2986-2989
19. Corwin HL: Anemia in the critically ill: The role of erythropoietin. Semin Hematol 2001; 38(Suppl 7):24-32
20. Corwin HL, Krantz SB: Anemia of the critically ill: "Acute" anemia of chronic disease. Crit Care Med 2000; 28:3098-3099
21. van Iperen CE, Biesma DH, van de Wiel A, et al: Erythropoietic response to acute and chronic anaemia: Focus on postoperative anaemia. Br J Anaesth 1998; 81(Suppl 1):2-5
22. Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79:1987-1994
23. Abel J, Spannbrucker N, Fandrey J, et al: Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 1996; 57:359-363
24. Krafte-Jacobs B, Levetown ML, Bray GL, et al: Erythropoietin response to critical illness. Crit Care Med 1994; 22:821-826
25. Bauer A, Tronche F, Wessely O, et al: The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev 1999; 13:2996-3002
26. Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
27. Poletes GP, Miller SF, Finley RK, et al: Blood use in the burn unit: A possible role for erythropoietin. J Burn Care Rehabil 1994; 15:37-41
28. Still JM, Belcher K, Law EJ, et al: A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995; 38:233-236
29. Georgopoulos D, Matamis D, Routsi C, et al: Recombinant human erythropoietin therapy in critically ill patients: A dose-response study. Crit Care 2005; 9:R508-R515
30. Stockenhuber F, Kurz RW, Geissler K, et al: Recombinant human erythropoietin activates a broad spectrum of progenitor cells. Kidney Int 1990; 37:150-156
31. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417; erratum, 1999; 340:1056
32. Shermock KM, Horn E, Lipsett PA, et al: Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005; 33:497-503
33. Corwin HL, Hebert P: Avoiding a blood transfusion: How much is it worth? Crit Care Med 2005; 33:672-674
34. Carson JL, Duff A, Poses RM, et al: Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055-1060
35. Hebert PC, Wells G, Tweeddale M, et al: Does transfusion practice affect mortality in critically ill patients? Am J Respir Crit Care Med 1997; 155:1618-1623